These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1457 related items for PubMed ID: 19332468
1. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB, LIFE Study Investigators. Circulation; 2009 Apr 14; 119(14):1883-91. PubMed ID: 19332468 [Abstract] [Full Text] [Related]
2. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients. Okin PM. J Electrocardiol; 2009 Apr 14; 42(6):584-8. PubMed ID: 19631946 [Abstract] [Full Text] [Related]
10. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Narayan P, Nieminen MS, Omvik P, Oparil S, Wedel H. Am Heart J; 2009 Jan 14; 157(1):177-84. PubMed ID: 19081416 [Abstract] [Full Text] [Related]
14. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. Li Z, Dahlöf B, Okin PM, Kjeldsen SE, Wachtell K, Ibsen H, Nieminen MS, Jern S, Devereux RB. J Hypertens; 2008 Jun 14; 26(6):1244-9. PubMed ID: 18475164 [Abstract] [Full Text] [Related]
15. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Julius S, Snapinn S, Dahlöf B, LIFE Study Investigators. Hypertension; 2004 Jul 14; 44(1):48-54. PubMed ID: 15173125 [Abstract] [Full Text] [Related]
17. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. J Am Coll Cardiol; 2005 Mar 01; 45(5):712-9. PubMed ID: 15734615 [Abstract] [Full Text] [Related]
19. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Olsen MH, Wachtell K, Beevers G, Dahlöf B, de Simone G, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Lyle PA, Nieminen MS, Omvik P, Oparil S, Wedel H. J Hypertens; 2009 Mar 01; 27(3):567-74. PubMed ID: 19262226 [Abstract] [Full Text] [Related]
20. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB. Eur Heart J; 2010 Sep 01; 31(18):2271-9. PubMed ID: 20601389 [Abstract] [Full Text] [Related] Page: [Next] [New Search]